ProMab Biotechnologies Overview
- Year Founded
-
2001
- Status
-
Acquired/Merged
- Latest Deal Type
-
Debt - PPP
- Financing Rounds
-
3
- Investments
-
1
ProMab Biotechnologies General Information
Description
Developer of recombinant proteins, antibodies and engineered cell lines intended to improve human health with a focus on the field of immunotherapy. The company offers its products through the integration of bioinformatics, molecular biology, protein expression, purification techniques, gene cloning, microbiology and immunology, using novel technologies, thereby helping to deliver research and diagnostic products and for the global biomedical research community through collaborations, partnerships and joint ventures with other biotechnology and bio-reagent companies.
Contact Information
Website
www.promab.com(Operating Subsidiary)
Corporate Office
- 2600 Hilltop Drive
- Building B
- Richmond, CA 94806
- United States
Corporate Office
- 2600 Hilltop Drive
- Building B
- Richmond, CA 94806
- United States
ProMab Biotechnologies Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ProMab Biotechnologies Comparisons
Industry
Financing
Details
000000
000000
ProMab Biotechnologies Competitors (47)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| GenScript | Formerly VC-backed | Piscataway, NJ | 0000 | 00000 | 000000000 | 00000 |
| BioLegend | Formerly Accelerator/Incubator backed | San Diego, CA | 000 | 000000&0 | ||
| Cytovance Biologics | Formerly PE-Backed | Oklahoma City, OK | 000 | 0000 | 000000&0 | 0000 |
| Novus Biologicals | Formerly PE-Backed | Centennial, CO | 000000&0 | |||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | 000 | 00000 | 0000000000. |
ProMab Biotechnologies Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ProMab Biotechnologies Patents
ProMab Biotechnologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230383002-A1 | Humanized bcma antibody and bcma-car-t cells | Pending | 31-May-2022 | 00000000000 | 0 |
| US-20230303708-A1 | Humanized bcma antibody and bcma-car-t cells | Pending | 18-Aug-2020 | 00000000000 | |
| EP-4199967-A1 | Humanized bcma antibody and bcma-car-t cells | Pending | 18-Aug-2020 | 00000000000 | |
| EP-4199967-A4 | Humanized bcma antibody and bcma-car-t cells | Pending | 18-Aug-2020 | 00000000000 | 0 |
| US-20230295331-A1 | Cs1- antibody and anti-cs1-car-t cells | Pending | 06-Aug-2020 | C07K14/7051 |
ProMab Biotechnologies Executive Team (3)
| Name | Title | Board Seat |
|---|---|---|
| John Wu | Chief Executive Officer & President | |
| Michael Simson | Chief Business Officer |
ProMab Biotechnologies Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ProMab Biotechnologies Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| One World Lab | 05-Dec-2017 | 0000000000 | Biotechnology | 0000 00 |
ProMab Biotechnologies FAQs
-
When was ProMab Biotechnologies founded?
ProMab Biotechnologies was founded in 2001.
-
Who is the CEO of ProMab Biotechnologies?
John Wu is the CEO of ProMab Biotechnologies.
-
Where is ProMab Biotechnologies headquartered?
ProMab Biotechnologies is headquartered in Richmond, CA.
-
What industry is ProMab Biotechnologies in?
ProMab Biotechnologies’s primary industry is Biotechnology.
-
Is ProMab Biotechnologies a private or public company?
ProMab Biotechnologies is a Private company.
-
What is ProMab Biotechnologies’s current revenue?
The current revenue for ProMab Biotechnologies is 000000.
-
Who are ProMab Biotechnologies’s investors?
NanHua Bio-medicine Company has invested in ProMab Biotechnologies.
-
Who are ProMab Biotechnologies’s competitors?
GenScript, BioLegend, Cytovance Biologics, Novus Biologicals, and Sorrento Therapeutics are some of the 47 competitors of ProMab Biotechnologies.
-
When was ProMab Biotechnologies acquired?
ProMab Biotechnologies was acquired on 13-May-2020.
-
Who acquired ProMab Biotechnologies?
ProMab Biotechnologies was acquired by Shanghai Shineton Investment.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
